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A roadmap towards personalized immunology
Sylvie Delhalle1, Sebastian F. N. Bode1,2, Rudi Balling3, Markus Ollert1,4 and Feng Q. He 1
Big data generation and computational processing will enable medicine to evolve from a “one-size-ﬁts-all” approach to precise
patient stratiﬁcation and treatment. Signiﬁcant achievements using “Omics” data have been made especially in personalized
oncology. However, immune cells relative to tumor cells show a much higher degree of complexity in heterogeneity, dynamics,
memory-capability, plasticity and “social” interactions. There is still a long way ahead on translating our capability to identify
potentially targetable personalized biomarkers into effective personalized therapy in immune-centralized diseases. Here, we discuss
the recent advances and successful applications in “Omics” data utilization and network analysis on patients’ samples of clinical
trials and studies, as well as the major challenges and strategies towards personalized stratiﬁcation and treatment for infectious or
non-communicable inﬂammatory diseases such as autoimmune diseases or allergies. We provide a roadmap and highlight
experimental, clinical, computational analysis, data management, ethical and regulatory issues to accelerate the implementation of
personalized immunology.
npj Systems Biology and Applications  (2018) 4:9 ; doi:10.1038/s41540-017-0045-9
INTRODUCTION
Continuous improvements in laboratory technologies and com-
putational biomedicine have enabled the generation and proces-
sing of vast amounts of data, prerequisites that will allow medicine
to evolve from a “one-size-ﬁts-all” approach to a more detailed
patient stratiﬁcation and future personalized treatment. With the
publication of the epochal report on Precision Medicine Initiative
in 20111 and USA President Obama’s announcement in his state of
the Union Address 2015 (https://obamawhitehouse.archives.gov/
the-press-ofﬁce/2015), precision/personalized medicine is becom-
ing one of the theme songs in biomedical research across the
world. Traditional approaches based on clinical symptoms and a
few classic laboratory markers can only provide incomplete
information on disease manifestations. Furthermore, molecular
and clinical heterogeneity among patients is very common in
many diseases, especially in multi-factorial complex diseases. For
instance, the immune responses following the same treatments
may be even individual-speciﬁc.2–4 As a clinical consequence,
some routinely used drugs, for example statins, widely prescribed
to lower cholesterol, can be beneﬁcial only to a small fraction of
patients while other drugs might even be harmful to certain
ethnic groups.5 Therefore, it is essential for researchers and
clinicians to identify the molecular and environmental factors that
determine whether and how an individual patient responds to a
particular therapy.
The move to personalized treatment ﬁrst requires the large-
scale unbiased analysis of genomic and molecular characteristics
of individuals experiencing deﬁned disease conditions to identify
reliable patient-speciﬁc biomarkers linking genotypes, molecular
proﬁles/endotypes, disease progression and “Omics” data and to
process them computationally to identify personalized
biomarkers.6–11 It is worthy to note that so far one of the most
ambitious personalized medicine trials (NCT02465060, known as
NCI-MATCH, launched in 2015) is recruiting thousands of
participants to differentially treat individual patients suffering
from solid tumors or lymphomas according to their genetic
abnormalities with one of the 23 selected drugs. In 2017, two
studies described therapeutic approaches using personalized
vaccination targeting patient-speciﬁc mutated tumor neoantigens
that gave very promising results, rising high expectations and
hopes with regards to personalized medicine, at least in
cancer.12,13 Interestingly, these recent accomplishments mainly
lay on establishing effective anti-tumor immunity. Therefore, it is
possible to develop personalized immunology that requires not
only to test for personal genetic markers, but to identify the
downstream targetable functional molecular markers and to
sequentially stratify patients using multi-levels of “Omics”
approaches, which shall be further advanced in personalized
oncology as well as immune-centralized disease studies.
THE NEED OF PERSONALIZED IMMUNOLOGY
Although the concept of personalized medicine in general has
been proposed for a while in the ﬁeld,11 its main successful
applications are obtained in the ﬁeld of cancer.
The unique feature of immune cells compared with other cell
types (e.g., tumor cells) in the human body is their capability to
shift between multiple activation states even under physiological
conditions, not to mention under pathological conditions. The
immune cells can at least switch between two states, resting and
stimulated states if not counting the often-existing in-between
gray areas or continuum zones. Our immune system is further
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complicated by many other states, including but not limited to,
immatured/matured, exhausted, “anergic”, senescent and many
others. These features render immunology a special layer of
complexity and further increase the difﬁculties in delineating the
underlying dynamic networks determining immune response
patterns and regulating their variances among individuals. The
enormous complexity of immune systems has badly called for the
application of systems biology/medicine to immunology. The
essential focus of systems biology is to study the emerging
properties of various layers of molecular, cellular and ecological
networks, instead of reductionism-based single components out
of intertwined cellular and molecular networks. Therefore, the
emerging properties of immune systems for the sake of the
excessive existence of inter-cellular and intra-cellular immune
networks14 cannot be revealed without the proper involvement of
and further development of systems biomedicine that has already
been successfully demonstrated in various related aspects of
oncology. Therefore, we need to systematically characterize and
proﬁle hundreds of different immune subpopulations in each
individual patient, which is the focus of systems immunology.15
Furthermore, compared with tumor cells, the memory capability
of our immune systems adds another layer of complexity to the
particular characteristics of personalized immunology. Indeed, the
responses of our immune systems are determined not only by
genetic factors, but also by environmental elements. The latter
such as exposed antigens will deﬁnitely affect functional
hysteresis of immune cells. The complex immune-related diseases
often display a mixture of various clinical symptoms and
traditionally, physicians mainly divide patients into subgroups
with one single disease based on their symptoms or in
combination with some blood markers (Fig. 1, Step 1). Due to
the subjective judgment on symptoms, physicians cannot easily
and accurately classify patients based on clinical symptoms alone.
To be able to more precisely stratify patients for precision and
personalized treatment, there exists a strong need to identify
reliable molecular biomarkers. With the development of various
types of high throughput techniques, we now possess approaches
that not only systematically measure frequencies of different
immune subpopulations and levels of various combinations of
activation/inhibitory markers, but also measure genome-scale
small and macro-molecules from whole tissues to cellular levels.
For instance, we can now perform immune subset deep-
phenotyping (e.g., with mass cytometry/CytoF), T-cell receptor/B-
cell receptor (TCR/BCR) repertoire sequencing, genome sequen-
cing, microarray/RNA-sequencing, proteomics, metabolomics,
epigenomics, microbiomics and other large-scale analyzes. Thus,
we currently have opportunities to obtain high-dimensional data
which are much more information-enriched and could be used as
basis for biomarker discoveries and patient stratiﬁcation.
The next generation of systems immunology is personalized
immunology that not only applies systems biological approaches
to investigate basic, translational and clinical immunology, but
also aims to identify personalized biomarkers based on multi-layer
chronological “Omics” and clinical data, to more precisely stratify
immune-related diseases and sequentially personalize treatments
(Fig. 1, Step 1–3). From the disease point of view, personalized
immunology focuses on inﬂammatory, infectious, autoimmune,
allergic and other immune-related diseases, which are apparently
out of the main scope of personalized oncology. In short, we need
to especially raise and develop personalized immunology, not
only due to the extreme high degree of complexity in immune
systems, but also attributable to the completely distinct diseases.
We here elaborate on some examples of immune-related diseases
such as infectious diseases, autoimmune diseases and allergy that
tempt to either identify novel biomarkers, or stratify patients, or a
combination of aforementioned purposes.
SELECTED EXAMPLES IN PRECISION/PERSONALIZED
IMMUNOLOGY
Related to the terms “systems medicine” or “systems biology”,
there are only a few studies registered at the major clinical trial
database (https://clinicaltrials.gov/). As expected, not that many
concern “precision”/“personalized” AND “immunology”/“inﬂam-
mation” (only around 200). Even among those, the majority is still
related to the ﬁeld of oncology. In Table 1 a non-exhaustive
exemplary list of trials with precision immunological aspects can
be found (HIV was excluded as it is not the focus of this review).
Notably, only a few of these listed immunology-disease studies
actually focus on measuring “Omics” data, while many others still
only investigate single aspects of a disease, or in a better scenario
a combination of several particular facets that do not clearly
specify a genome-scale assessment, indicating again the high
demand for further development of personalized/precision
immunology.
While some issues including the timely collection of time-series
samples have been successfully exercised in many classical clinical
trials,16–19 other challenges still exist in several areas, such as
coordination, ethics approval, data protection, high-frequency or
dense sampling, sample measurement/data generation, data
management, integration and analysis. First, the coordination of
complicated clinical trials to obtain multi-layer “Omics” data itself
is already challenging. That is, to convince, to organize and to
synchronize activities of various partners such as clinical partners,
biobanking, cell sorting facilities, experimental laboratories, data
managers, computational analysis groups, sample transportation
logistics among different partners requires the involvement of
high-level leadership. Second, many biological processes such as
transcription and metabolism change very fast and almost all the
biological processes and immune cell functions are under the
regulation of circadian rhythms and other negative feedback-
based mechanisms. We might have to take time-series samples
with short intervals for some immune diseases according to the
Nyquist-Shannon sampling theorem.20 Based on our experience in
clinical trials, it requires completely different magnitudes of efforts
and resources to perform time-series sampling with intervals in
the order of years, months, days, hours or minutes. So far, most
longitudinal cohorts largely sample from patients with an interval
of years/months or in the best cases weeks or days, which still only
entails routine efforts. Third, how to fully make use of same small
quantities of patient samples or biopsies for a simultaneous
measurement of different types of molecules and cells is also ﬁlled
with challenges because different types of molecules might
require very different procedures of sample preparation. Fourth, a
huge challenge is the integration of resulting multi-layer “Omics”
data sets with clinical data since we are fully aware how difﬁcult to
handle even just a single type of genome-scale data sets is. Fifth,
what seems to be simple in the aspects of ethic authorization and
patient data protection, in reality is highly challenging, which will
be discussed in the later sections. Last but not least, we also need
to overcome other complicated aspects, to name but a few, the
burden of high ﬁnancial costs of multi-“Omics” approaches, which
is related to not only genome-scale measurement, but also a
larger number of personnel required for dense time-series
sampling, and to conquer the barriers of distinct expertize and
standards of involved laboratories/computational groups (Table 2).
Our ongoing study (NCT02931955) that only focuses on a model
disease to establish a multi-layered time-series approach to
understand its genetic and molecular characteristics has to
overcome all the aforementioned issues. In the following
paragraphs, we highlight some examples and discuss the
potential future focuses of selected ﬁelds of preclinical and clinical
research.
A roadmap towards personalized immunology
S Delhalle et al.
2
npj Systems Biology and Applications (2018)  9 Published in partnership with the Systems Biology Institute
1
2
3
4
5
6
7
8
9
0
()
:,;
Autoimmune diseases—systemic lupus erythematosus (SLE)
SLE is an autoimmune disease, predominantly affecting young
women, with a cutaneous, vascular and other auto-inﬂammatory
manifestations. Especially kidney involvement in the form of
nephritis determines the prognosis. As of today no single
treatment is curative and there is enormous heterogeneity in
both clinical and molecular patterns.21 Therefore, it is essential to
stratify patients for improving personalized treatments. For this
purpose, Banchereau et al. have ﬁrst sampled blood from
hundreds of pediatric SLE patients through a longitudinal cohort
and analyzed the whole blood transcriptome. Following that, they
have applied weighted gene co-expression network analysis
approaches22 to identify patient-speciﬁc co-expressed modules
that were best correlated to clinical traits over time. They then
used clinical-relevant patient-speciﬁc modules to cluster and
stratify patients into seven patient groups. Accordingly, they were
also able to precisely stratify additional test patients into
corresponding subgroups. These co-expression modules might
be highly valuable to stratify patients into subgroups, which
requires longitudinally sampling, however, that might be not
accessible for most patients.
While this is an important step forward, this concept still needs
to be translated into clinical practice so that a patient stratiﬁcation
like this can be used for the identiﬁcation of a potential
therapeutic or disease-monitoring approach. To further evaluate
this potential, an integration of genomic, metabolomics and other
layers of data is needed. Moreover, the information of the whole
blood transcriptome as performed21 might still only partially
reﬂect all the manifestations of SLE, and we might even overlook
some important disease-speciﬁc or patient-speciﬁc changes that
could been “averaged” out due to the fact that the given genes
might be expressed in multiple types of immune cells.
In parallel, we could also stratify patients with SLE using protein
information, such as autoantibodies. Budde et al. have recently
developed a middle-scale assay with up to 86 antigens to detect
diverse autoantibodies involved in various pathways.23 Using such
Fig. 1 A roadmap proposed towards personalized immunology. There exist both horizontal and vertical roadmaps towards personalized
immunology. Vertically, to translate sample stratiﬁcation to clinical therapies, we need to utilize the state-of-the-art “Omics” analysis and
network integration approaches to stratify patients into subgroups and then implement personalized therapeutic approaches to treat
individual patients, which needs to overcome various types of barriers at different steps. Horizontally, we might need to go through at least
7 steps to enable personalized immunotherapies, 1) classic symptom-based approach, 2) deep phenotyping approach, 3) multi-layer “Omics”-
based proﬁling, 4) cell type-speciﬁc “Omics”, 5) state-speciﬁc “Omics”, 6) single-cell (sc) “Omics” and dynamic response analysis of immune cells,
7) integrated network analysis. FACS, ﬂuorescence activated cell sorting; TCR/BCR, T cell receptor/B-cell receptor; DEG, differential expression
gene; PEEP, personalized expression perturbation proﬁle; SSN, sample-speciﬁc network; SVM, support vector machine; KNN, K-nearest
neighbors; under the ﬁrst layer (the so-called stratiﬁcation layer), different colors of patients indicate individual patients with different cellular
and/or molecular proﬁles while brackets represent patient subgroups; under the second layer (the so-called technique layers), different small
circles with distinct colors indicate different immune cells while big circles represent patient (sub)groups; under the technique layers, the
snapshot of microarray representing either microarray-based or RNA-seq-based transcriptome analysis; under the third layer (the so-called
therapeutic layer), the syringes with different colors or tonalities indicate different therapeutic approaches; P1,..., Pn at step 7 designate
different patients; G1, G2, G3, G4 represent different genes, the arrows between them representing regulatory relationships. Three images in
the second layer of step 1 are used with permissions from Fotolia.com
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an approach, they were able to separate SLE patients into ﬁve
clusters. Such an autoantibody-based approach might also
contribute to precise patient stratiﬁcation, especially for auto-
immune diseases. We believe that with the additional information
on other layers of “Omics” data and the extension to a wider
spectrum of autoantibodies, more precise stratiﬁcation of SLE
patients should be possible in the near future.
Allergic diseases—allergen immunotherapy
Allergies affect >10% of most countries’ populations and are cause
for signiﬁcant secondary diseases and ﬁnancial burden.24 Cur-
rently, the only curative option is allergen immunotherapy (IT).25–
27 It works through complex immunological processes starting
with mast cell and basophil desensitization that lead to changes in
the T-cell compartment28 and ﬁnally modiﬁcations in B cells as
well as mast cells, basophil, and eosinophil allergen response
patterns.25
The component characterization of allergens29 has considerably
improved molecular diagnostics of allergies, for example, the
differentiation between double sensitization to bee and wasp
venom and cross-sensitizations, which helps to establish tailored
IT.30,31 Furthermore, with higher-resolution component analysis
we were able to show that predominant IgE sensitization to Api m
10 in individual patients might be a good predictive marker for the
failure in IT treating honey bee venom allergy.32 However, success
of the therapy cannot be predicted by classical approaches
including measuring speciﬁc IgE or IgG4, skin testing or basophil
activation tests.27,33
In order to better predict the success of IT, Ryan et al.27 have
analyzed the TCR repertoire and expression of a preselected list of
24 genes of single CD4+ T-lymphocytes of peanut allergic patients
undergoing oral IT, and of healthy controls. Patients’ CD4+ T-cells
could be clustered into seven groups that showed complex
phenotypic changes in CD4+ lymphocytes over the course of oral
IT, and distinct temporal changes were especially observed in the
antigen-speciﬁc CD4+ lymphocytes. Patients who successfully
passed an oral double-blind placebo controlled food challenge
demonstrated a shift towards a “tolerant” Th2 phenotype only
3 months after the induction of IT.27
Although such a wide-spectrum analysis is already quite
powerful in predicting the success of IT, this information only
represents a small fraction of all the manifestations that truly
reﬂect the patients’ immunological proﬁles. Systemic level deep
phenotyping of various relevant immune subsets and proﬁling
genome-scale expression or concentration levels of transcripts,
proteins and metabolites of each type of relevant immune cells
should provide much more precise and unbiased molecular
characterization and stratiﬁcation in combination with classical
clinical information, which for instance is being pursued in the
clinical trial initiated by us (NCT02931955, Table 1).
The IT itself will be the focus of future research and become
more precise and tailored to individuals in the next years. As an
initiative, the recombinant allergens produced for diagnostic
purposes provide an interesting option for future tailored personal
IT and might replace todays’ crude whole venom/allergen extracts
that might vary in their composition.34 This might help to reduce
the number of patients suffering from side effects of the therapy
as it affects up to 40% of patients undergoing subcutaneous IT,35
which need to be lowered to ensure patient adherence, with the
assistance of “Omics”-based stratiﬁcation.
Infectious diseases
Infectious diseases are a major cause of morbidity and death
worldwide, fostered by diagnosis sub-efﬁciency and poor access
to treatment, especially in developing countries, whereas rising
antimicrobial resistance appears as a main challenge to global
public health. Monitoring and cure of infectious diseases isT
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particularly challenging from the view of personalized medicine,
since it ﬁrst requires comprehensive understanding of both host
and pathogen’s individual features prior to elucidating how their
interactions determine the outcomes of infection in different
patients. Transcriptomic studies of patients’ peripheral blood
mononuclear cells (PBMCs), CD4+, and CD8+ T cells during the
course of infection were investigated to identify genes associated
to survival, exhaustion or memory phenotype.36,37 However, these
studies did not assign predictive biomarker values to the
identiﬁed lists of genes.
Inter-individual and intra-individual variability in adaptive and
innate immunity, as well as age, gender, ethnicity, microbiome,
environmental factors (also known as exposome) or existing
diseases inﬂuence the overall responses to antigens. Systemic
studies38 of these parameters with regards to the response to
vaccines will probably help to predict vaccination outcomes, by
identifying molecular signatures induced after vaccination,
unraveling their biological causative mechanisms, and assessing
their predictive value towards a responder status.39 In this regard,
systems vaccinology could allow for identiﬁcation of early
personalized molecular signatures linking to vaccination, which
could monitor or predict the efﬁcacy of a particular vaccination
strategy or could help identify patients at risk for systemic
reactions after vaccination.40 Through a transcriptomics analysis,
Fourati and coauthors identiﬁed an age-related signature and a
15-gene signature predictive of vaccine hypo-responsiveness to
hepatitis B virus surface antigen in naïve older adults.41 Possibly
due to the fact that the transcriptomic analysis was based on
whole blood samples, their predictive power was quite limited.
These examples show that the ﬁrst shots applying “personalized
immunology”-like approaches to infectious diseases not only
enable researchers to fully document the changes occurring in the
Table 2. Summary of key challenges and the potential solutions towards personalized immunology
Items Key challenges Potential solutions
1 Genome-scale or ﬁner-scale analysis on “averaged” data of
heterogeneous cell types from body ﬂuids (e.g., blood or PBMC) or
biopsies
Cell-type-speciﬁc and state-speciﬁc “Omics” analysis on sorted immune
cells
2 “Averaged” results of heterogeneous individual immune cells Single-cell “Omics”
3 Lack of disease progression and clinical-outcome predictive,
prognostic and early-warning tipping-point biomarkers
Dense time-series “Omics” measurement and analysis along
longitudinal studies
4 Lack of comprehensive proﬁling of various types of molecules Multi-layer “Omics” and integrated experimental and computational
analysis
5 Focus on our own human cells Also with skin, lung, gut, and reproductive tract microbiome analysis
6 Lack of large effects of identiﬁed SNVs on the diseases or symptoms
of interests
Selection of patients or subjects with more deﬁned inclusion or
exclusion criteria, e.g., removing those with comorbidity; combinatorial
effects of higher number of SNVs with more powerful computers
7 Availability of research-focused genetic analysis tools Clinics-orientated standardized genetic analysis tools with higher
accuracy, stability and computational power
8 Only a small fraction of patients with up- or down-regulated
biomarkers identiﬁed by group-wised approaches
Personalized expression perturbation proﬁles of each individual
9 Biomedical interpretation for biomedical researchers or clinicians
using machine-learning based classiﬁcation approaches not
provided yet
Personalized expression perturbation proﬁles of each individual
10 Unreliability and irreproducibility in identiﬁed single or a panel of
molecular biomarkers
Standardization in clinical sampling procedures, sample measurement,
data management and analysis; Absolute quantiﬁcation of biomarkers
of interests using a large-number of “Omics” data sets as a reliable
common reference; Personalized sample-speciﬁc network (SSN)
11 Relevant immune cells or molecules of interests often show
nonlinear dynamic characteristics
Time-series space-state analysis
12 Instability of transcripts and metabolites Proteomics-based analysis
13 Lack of information of immune cells about environmental exposome Epigenomics-based analysis
14 Massive unstructured and unstandardized clinical data Reliable and efﬁcient text-mining tools
15 Lack of integration of prior knowledge on disease mechanisms with
potential biomarkers
Establishment of molecular maps for different diseases.
16 Fragmented, unstandardized, unsecured, undigitized, unstructured,
uncentralized, and ever-increasing big data
Dedicated big-data management platforms and shared national and
international infrastructure with long-lasting update.
17 Classic informed consents (ICs) with deﬁned duration and research
purposes
Broad or dynamic ICs
18 Threat of patient data privacy due to wide usage of social-media or
wearable-instruments derived clinical or behavior information
New anonymization and pseudonymisation approaches of patients’
identiﬁcation
19 Group-wised approaches to assess efﬁcacy and safety of candidate
drugs
Separate evaluation of effects on individuals or subgroups of patients
20 High and long-lasting ﬁnancial cost To adjust and extend the current funding period framework for most
agencies; Closely working with health insurance providers to
differentially treat patient subgroups
21 One-cut pharmaceutical production pipelines Multi-“Omics”-guided customized production pipelines
Literature citation is directly inserted through the main text due to a large-number of references.
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host after pathogen transmission or its vaccine counterpart, but
also provide a major tool to predict the outcomes of infection or
vaccination before it occurs.
MAJOR CHALLENGES TOWARDS PERSONALIZED
IMMUNOLOGY
From whole tissue to cell-type-speciﬁc and state-speciﬁc “Omics”
So far, most of genome-wide studies report on “averaged” results
of different immune subpopulations, e.g., from PBMCs or even
whole blood or other body ﬂuids or biopsies (Table 2). Those
“averaged” results of heterogeneous cell types prohibit further in-
detail molecular proﬁling and functional evaluation of individual
cell types and their interactions in complex diseases.42 Although
advanced in-silico cell deconvolution approaches have been
recently developed to extract cell-type speciﬁc information from
whole tissues,43 they are suffering from serious limitations. For
instance, it can mainly fruitfully analyze groups of patients vs.
healthy controls, which apparently contrasts to the requirements
of personalized medicine. Therefore, identifying key molecular
and cellular players in personalized immunology can only be
successful if separated speciﬁc cell subpopulations will be
assessed regarding their “Omics” data on a more and more
precise level, e.g., starting from analyzing CD4+ T cells and then
further separating them into their subtypes e.g., regulatory T cells
(Tregs), Th1, Th2, Th17 and others. One step further, many
diseases are mainly characterized by dysfunction in particular
subsets of immune cells at particular activation or other functional
states while the development of those immune cells is intact. For
instance, the tumor inﬁltrating CD8+ T cells predominantly display
an exhausted phenotype (state) and the magnitude of reinvigora-
tion of peripheral exhausted T cells in relation to pretreatment
tumor burden determines clinical outcomes of individual
patients.44 Unless we perform “Omics” analysis on the very sorted
subsets of immune cells at the given states, including but not
limited to, memory vs. naïve, resting vs. stimulated, exhausted vs.
non-exhausted T cells45 (Fig. 1, Step 4–5), we could not unbiasedly
ﬁgure out the myriad facts whether and how particular subsets of
immune cells at the given states could contribute to or predict the
clinical outcomes of speciﬁc patients following treatment. This
demand to more deeply investigate cell-type-speciﬁc and state-
speciﬁc “Omics” analysis (Fig. 1, Step 4–5) is further complicated
by tissue-resident immune cells, which might display completely
different molecular patterns between different tissues, as do
human memory T cells from bone marrow and PBMC for
example.46 The tissue-resident immune cells might also contribute
to the pathogenesis of many diseases. The state-of-the-art
multichannel ﬂuorescence activated cell sorting (FACS) followed
by “Omics” analysis permits such an aforementioned assessment.
Single-cell (sc) “Omics”
Cellular type-based “averaged” approaches have made major
contributions in understanding molecular networks and functions
of cells. However, no single cells even for the same cell type are
identical and we do not know what the “averaged” values exactly
mean (Table 2). Such distinction among different individual cells
could be caused by mutation, stochastic variation or environ-
mental perturbations.47, 48 The difference might be reﬂected on
various molecular levels (DNA, coding and noncoding transcrip-
tion, translation, metabolism, epigenetic modiﬁcations and other
levels). The molecular heterogeneity among individual cells might
eventually cause functional heterogeneity.49 Such molecular
heterogeneity might also be attributable to the various activation
stages, which might be particularly true for immune cells.
Based on recent breakthroughs (Fig. 1, Step 6) in sc-
transcriptomics,50 sc-proteomics51 and even simultaneous mea-
surement of epitope and transcriptomics in single cells,52 we are
now in a unique position to characterize the molecular and
functional heterogeneity of rare cell populations. Signiﬁcant
progress has already been made in sc-studies to better
characterize individual tumor cell heterogeneity in cancer and
brain as well as to illustrate heterogeneity of certain immune cells,
e.g., macrophages53 and dendritic cells.54
Furthermore, recent advances in epigenetics have allowed us to
perform sc-epigenomic analysis55,56 in various types of cells, such
as embryos,57 primary lung adenocarcinomas, ﬁbroblasts,58 and
hepatocytes.59 More excitingly, advanced techniques have also
been developed for sc-metabolomics analysis, especially for
analyzing those circulating cancer cells that lead to metastasis.60
However, these approaches have yet to be comprehensively
applied to the rare populations of immune cells, for instance,
including Tregs,61 natural killer cells, innate lymphoid cells, and
others. In further steps, these methods could be combined with
imaging techniques, e.g., ImageStream that combines the power
of ﬂow cytometry and microscope, to further enhance the
knowledge on immune cell function, protein–protein interaction
and cell–cell interaction.42 Applying these multi-omics approaches
to a wider setting relies on maximization of coverage, accuracy,
and reproducibility in the coming years and will allow more
precise predictions from geno-type to endo-type to pheno-
type.42,56
The next challenging question is to which degree we can apply
single-cell based analysis to diagnostic or prognostic purposes in
real clinical settings since the heterogeneity among individual
cells might be even higher than the heterogeneity among
individual patients. One can envision that the heterogeneity
degree for a given cell type might increase or decrease in patients
with certain diseases. If this is the case, the heterogeneity degree
or the frequencies or clusters of ﬁnely-characterized cell subsets53
can be used as biomarkers. The number of required single cells to
provide reliable insights into the heterogeneity of gene expres-
sion, methylation or metabolism has to be balanced between the
analysis cost and required statistical power. With the decreasing
cost in sequencing techniques, we shall have more power to
identify reliable diagnostic and prognostic markers from isolated
single immune cells for immune-related diseases. Although a few
clinical trials are ongoing or were just ﬁnished (e.g., NCT02929745
and others, Table 1), no work has so far reported the usage of sc-
transcriptome to identify diagnostic or treatment-outcome pre-
dictive biomarkers in clinical studies, which will be foreseen in the
coming years.
Longitudinal studies and dynamic analysis
While the concept of prospective longitudinal follow-up is a key
element of clinical studies to help identify prospective risk factors,
prognostic and treatment-efﬁcacy biomarkers for diseases (Fig. 2),
this still needs to be implemented in modern omics-based research
(Table 2). It might be supported by establishing a lineage-tracing
tree retrospectively as demonstrated regarding acquisition of
mutations in cancer cells.56 Moreover, establishing longitudinal
cohort studies is essential for detecting predictive biomarkers from
“Omics” analysis, e.g., the critical transition early-warning biomar-
kers62 (Fig. 2a), before the appearance of apparent clinical
symptoms,63 when it might be often too late for an effective
therapy or cure to many chronic diseases.64 Identiﬁcation of those
early-warning biomarkers could profoundly help us to decide
when and how to apply preventative treatments to many chronic
diseases which are incurable so far (Table 2). This will then need to
be applied to a prospective approach in a personalized manner.
Heterogeneity in patients is reﬂected not only in the expression
levels of coding and non-coding genes and proteins, concentra-
tion of metabolites, activity of signaling transduction proteins, or
combination of them, but also in the resulting molecular
interaction networks, especially in the dynamic response patterns
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and functional output of the networks following physiological or
pathological stress. However, all the “static” biomarkers lack of
information on any underlying molecular mechanism, which, at
least partially, explains the current conundrum why most of
biomarkers are not necessarily suitable therapeutic or prognostic
targets. In order to provide mechanism-based biomarkers and the
following stratiﬁcation of patients, the pioneers, e.g., Kholodenko
and his colleagues have already started to explore novel
prognostic markers by simulating the dynamic output of relevant
signaling transduction pathways based on transcription expres-
sion levels measured in individual tumor patients.65,66 Strikingly,
they have already successfully shown that the various output
indexes, such as the maximal amplitude (A), the activation
threshold (K50), and the Hill exponent (H) of the Jun N-terminal
kinase signaling responses of tumor cells (Fig. 1, Step 6), can be
used to predict poor or favorable survival of patients with
neuroblastoma.65
In the immune systems, the degree of heterogeneity is even
more complex not only regarding numerous types of immune
cells, but also various states of immune cells, and even transient
cell types with bidirectional-convertible plasticity. The hetero-
geneity degree is even further complicated by the interactions of
such a broad range of immune cells. On a molecular level, it has
already been demonstrated that the gene modules that were
organized based on the transcript expression patterns in the
peripheral blood of elderly individuals can also be used to stratify
those individuals into two completely different clinical and
immunological states.67 More detailed work is expected to
characterize various types of molecules, not only in signaling
transduction dynamics (Fig. 1, Step 6), but also in dynamic
patterns of gene expression and epigenetic modiﬁcation (Table 2)
of the particular isolated immune subsets that should be able to
provide much better predictive and stratiﬁcation power (Fig. 2b,
c). To the best of our knowledge, this promising direction is
unfortunately still missing in immunology.
With the possibility to obtain time-series large-scale measure-
ments on various types of molecules and immune cells of patients
within well-designed longitudinal cohorts, we will be in a unique
powerful position. We will be able not only to describe the
molecular and cellular dynamic patterns68 (Fig. 2a–c), but also to
predict possible upcoming immune state changes of the patients.
The well-established space-state models69–71 that are widely used
in various ﬁelds such as ﬁnance, ecology, population dynamics,
and weather forecast should be adaptable and utilizable in
immune state prediction using time-series data sets of long-
itudinal cohorts (Table 2). There are at least three ways to predict
immune disease states, also known as attractors in mathe-
matics.72,73 One can build state-space models by using dynamic
measurements of various layers of molecules within each type of
relevant immune cells, or using dynamic measurements of
frequencies and functional markers, such as activating or
inhibiting receptors or cytokines/chemokines, or cytotoxic med-
iators of each type of relevant immune cells. Ideally, one might
need to combine both dynamic patterns of various layers of
molecules and of various types of immune cells since with the
known activating or inhibiting receptors alone we cannot reveal
all the functional aspects and response potential of the given
immune cells. Only in this way, one could make full use of the
precious time-series large-scale data sets to predict future immune
disorders or disease progression74–76 while keeping in mind the
apparent drawbacks77 of the current state-space models, such as
inability to predict long-term trajectories.78
Microbiome analysis
There is a clear link between the human gut microbiome and the
development of immune-related diseases, e.g., inﬂammatory
bowel disease and allergies.79,80 In general, higher diversity of
one individual’s microbiota is correlated with a reduced risk for
the development of asthma and other allergies and can to some
degree even predict the development of allergies.81,82 Using a
machine-learning approach, microbiome data were used (Fig. 1,
Step 3), for example, to stratify patients with irritable bowel
T T T T T
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Fig. 2 Longitudinal studies and dynamic measurement are critical
for discovering various types of biomarkers. a Longitudinal follow-
up of individual patients with multilayer “Omics” analysis is essential
for identifying different types of biomarkers. The check marker at
the given time point indicates the necessary “Omics” measurement
and clinical assessment for revealing the given type of biomarker
while the cross symbol indicates an unnecessary involvement at the
given time point for the given type of biomarker. b Time-series
“Omics” analysis of the cultured isolated immune cells from the ﬁrst
visit (T0 at panel a) following certain stimulation or stresses will also
be able to help extract various types of biomarkers. c Various types
of dynamic patterns of different pathways or modules or subnet-
works of the given relevant type of immune cells isolated from
PBMC or other tissues of individual patients might be valuable for
patient subgroup stratiﬁcation. Subnetwork activities at the given
time can be deﬁned either by the expression levels of the co-
expressed genes, or by the expression levels of the effector genes
(such as cytokines) or any other readouts which could deﬁne the
activities or outputs of the given pathway or subnetwork or module
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syndrome successfully into subgroups.83 Tejdo et al. were able to
correctly identify patients with Crohn’s disease based on their
fecal microbiota composition.84 While the lung historically was
considered microbe-free, knowledge on the human lung micro-
biome is steadily increasing over the last years, thanks to the
advantages in next-generation sequencing based techniques.85
The human microbiome data set (http://hmpdacc.org) shows that
an abundance of bacterial species are present in the lung and this
colonization is different in asthmatic individuals compared to
healthy persons.86,87 Furthermore, a reduction in microbiota
variety after antibiotic treatment is clinically correlated with a
reduced bronchial hyper-responsiveness.87,88 This hints at an
interplay between lung microbiome and asthma development.
Reduced diversity of skin microbiota was also found in the
patients with atopic dermatitis89,90 or psoriasis.91 These studies
show that skin, gut, and lung microbiome could potentially be
used as diagnostic and treatment-efﬁcacy biomarkers in the
context of many other immune mediated diseases. Furthermore,
reported inter-individual differences in the gene content of
human gut bacterial species92 might designate the necessity to
develop approaches to use the additional layers of information on
patient-speciﬁc microbiome to precisely stratify patient’s sub-
groups (Table 2). Ultimately, this should not only cover diagnostic
or prognostic aspects, but move towards therapeutic approaches
as well.79
Personalized network and computational analysis
Following the generation of large-scale “Omics” data, the next
challenging step is to computationally analyze these data to
precisely stratify patients into subgroups based on various sets of
biomarkers at different molecular layers in combination with
frequencies of immune cell subsets, clinical information, and
epidemiological data. Signiﬁcant efforts have already been put to
identify genetic variants that are associated with certain traits, for
instance, identiﬁcation of robust association between single
nucleotide variant (SNV) with single traits or complex diseases.93
Although many computational algorithms have been developed
for this purpose, unfortunately, most of the identiﬁed SNVs have
very small effects on the given traits or diseases. Not mentioning
any other type of “Omics” data, with unprecedented amount of
genomic sequencing data following the announcement of the
precision medicine initiative in many countries, we deﬁnitely need
more powerful alignment and assembly algorithms.93 Those
approaches are critical to empower us to perform more accurate
variant call and whole-genome sequencing analysis94 to identify
patient-speciﬁc variants that contribute to the pathogenesis of a
given disease in an individual patient. In this context, clinics-
orientated vs. research-focused genetic analysis tools that require
higher accuracy, stability, and computational power/speed are still
underdeveloped.
Traditionally, clinicians have already utilized the information of
metabolite concentration, e.g., serum glucose levels for diagnostic
purposes (Fig. 1, Step 1). More recently, researchers have already
developed and applied various bioinformatics tools to utilize
large-scale data, i.e., metabolomics data to seek biomarkers95 (Fig.
1, Step 3). For instance, researchers have already commenced to
use metabolomics data as cancer early predictive, diagnostic and
therapeutic treatment response biomarkers.96 Researchers have
also made use of metabolomics data as biomarkers for various
autoimmune diseases, such as Crohn’s disease97 and recently also
rheumatic diseases.98 Since metabolites are in one of the effector
layers of cellular functions, there are certain advantages to utilize
metabolomic data as biomarkers. Although technically more
challenging compared to mRNA analyses, the intracellular
metabolome of a speciﬁc type of immune cells should provide
not only novel insights into immune-metabolism,99,100 but also
more precise cell-type-speciﬁc biomarkers.
Current efforts to identify biomarkers and stratify patient
subgroups are mainly put on transcriptomic data that are
obtained either from probe-preselected microarray measurements
or unbiased RNA-sequencing based techniques. Many statistical
approaches were applied to identify differentially expressed
biomarkers (Fig. 1, Steps 3 and 7). However, the biomarkers
discovered based on those group-wised approaches are up- or
down-regulated only in a small fraction of patient groups
compared with healthy controls.101 Furthermore, due to the
limited number of training samples, bioinformaticians often
generate a long list of differentially expressed biomarkers.
However, to successfully apply this to the real life of clinical
settings, the number of biomarkers in the panels should be
limited. Machine learning approaches, such as Bayesian classiﬁers
and support vector machine have been successfully applied to
various studies to stratify patient groups.102 However, machine
learning approaches are black boxes for most of biologists and
clinicians that can hardly provide biomedical interpretation (Fig. 1,
Step 7). To address this limitation as well as the huge
heterogeneity among different patients even for the same
diseases, Barabasi and his group have recently developed an
approach to utilize the personalized expression perturbation
proﬁles of each individual based on transcriptomic measurement
as the barcode for each individual for the studied disease101 (Table
2). They found that the fraction of genes from the identiﬁed
disease module perturbed in an individual subject can accurately
predict the status of the given individual (Fig. 1, Step 7). Compared
with the machine learning approaches, this combinatorial model
could be more explicit. However, like any other method, this
approach has also its own limitations, such as one needs to ﬁrst
decide and optimize the threshold to deﬁne whether the genes
are perturbed or not and one is still not sure whether this method
is beneﬁcial for a further stratiﬁcation of the patients with the
same diseases into subsidiary groups.
Unreliability and irreproducibility in identiﬁed single or a panel
of molecular biomarkers has already caught enormous concerns
by both academia and pharmaceutical companies.103,104 Such
irreproducibility could be caused by either technical issues or
intrinsic biological variance itself or a combination of both factors.
Ubiquitous existence of irreproducible biomedical results could
also be attributable to a lack of standardization in error-prone
affairs, such as sample preparation, sample measurement,105 data
analysis106 or the combination of all the steps (Table 2). For
instance, regarding clinical sample measurement, worldwide
standardization of a diagnostic test is the development of the
international normalized ratio (INR) to measure the extrinsic
pathway of coagulation. Initially the prothrombin time was used
but varied greatly by the various laboratories providing the results.
An international sensitivity index of the reagents used is thus
determined by testing an international reference tissue factor
(ISI).107 A similar approach might be extended and adapted to
different “Omics” measurements.
In the meantime, to recapture the reported expression or
concentration level changes of individual molecules such as
mRNAs, proteins or metabolites are tricky, not only due to their
dynamic characteristics of nonlinearity, such as circadian rhythm-
driven ﬂuctuations and technical challenges, but also due to
environmental, nutritional or even emotional inﬂuences. In order
to mitigate technical challenges that are partially responsible for
data irreproducibility in genome-scale mRNA measurement, Seita
et al. have used a large number of microarray data sets as a
common reference to estimate the absolute expression values of
each gene of interest108 (Table 2). In this way, one could at least
have opportunities to quantify the biomarkers of interest, to more
precisely compare them with the counterparts of control groups in
order to support clinical decision making. Otherwise, due to the
variability caused by technical challenges alone, one cannot
determine whether the given genes or other biomarkers have
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been really up-regulated or down-regulated in the given patients
and therefore might conclude a wrong diagnosis or even suggest
an inappropriate treatment. More recently, Chen and his
colleagues have proposed to use networks that are supposed to
be more resistant to both technical and biological variances,
instead of single-molecular biomarkers109 (Table 2). They identi-
ﬁed personalized SSN biomarkers by calculating the differential
correlation networks between the reference groups and that
target group combining the reference groups with the single
sample from the patient of interests using transcriptomic data
(Fig. 1, Step 7). They have successfully demonstrated a very high
performance (>98% accuracy) when classifying tumor samples.
Importantly, using their approaches they identiﬁed that most of
the hub genes in the differential correlation networks are non-
differentially expressed and they have experimentally validated
their functional importance in drug resistance. Coincidently, the
discovery of non-differentially expressed key genes has also been
demonstrated by our previous work.110 Those network biomarkers
represent a novel future direction which possibly renews the
deﬁnition of traditional biomarkers and could be widely used in
personalized medicine including personalized immunology, since
it requires only a single sample for each individual. However, one
still needs to be cautious when it is applied to immune diseases
due to extra dynamic characteristics of various types of immune
cells during the disease progression and even just due to
biological circadian rhythm.111 Following activation, if the dynamic
characteristics of the relevant immune cells or of the molecules of
interests show nonlinearity, which might be the case in many
situations, a simpliﬁed network-based stratiﬁcation approach will
not be so efﬁcient anymore.
Due to the relative stability of proteins, proteomics-based
computational approaches have been developed to identify more
robust biomarkers, especially in the ﬁeld of oncology.112,113 A
growing body of evidence shows that many diseases are
developed following exposure of various types of acute or chronic
environmental factors (Fig. 1, Step 3), it therefore makes sense to
assess their effects on the epigenetic states of different cell types
including immune cells. However so far, few methods have been
established to identify epigenetic biomarkers.114,115 In order to
further improve the accuracy and conﬁdence levels, which is
extremely important in the clinical setting, integration of various
layers of molecules and clinical information is essential to identify
reliable multilayer biomarkers and to more precisely stratify
patients into appropriate groups for personalized treatment (Fig.
1, Step 3). For instance, in clinical settings, diagnostic false
negative rates might be more harmful than false positive rates in
many type of diseases, and another way around for many others.
Conversely, in the research ﬁeld, the two types of rates might be
equally treated. Last but not least, we also need to develop
reliable and fast text-mining tools to extract clinical information
from unstructured and unstandardized clinical data116 (Table 2).
This aspect is also not trivial since the clinical data in many
hospitals or clinical centers still do not make the structured and
standardized prescription or description compulsory while the
volume of such data is exponentially increasing.
With the development and accumulation of our understanding
in molecular mechanisms of a wide spectrum of diseases,
researchers have already initiated concepts and approaches to
reconstruct, visualize and analyze diseases molecular maps, such
as the Alzheimer’s disease map and the Parkinson’s disease
map.117,118 We are convinced that with the support of prior
knowledge, i.e., disease maps (Table 2), we should be able to not
only more precisely stratify patients according to the particular
pathways/subnetworks that were detected in the given individual
patients, but also in a much more intuitive manner to support
clinicians to better understand the pathological mechanisms, to
make decisions and to differentially treat patients. However, in
contrast to the neuron-focused maps in neurodegenerative
diseases, different types of immune cells with different dynamic
stages that are often involved in immune-related disorders, make
the development of such disease maps more challenging. The
fundamental limitation in stratifying patients using disease maps
is whether we could identify any novel subgroup of the patients of
interests based on prior knowledge, which might be not so critical
anymore if the diverse mechanisms underlying the given disease
have been well understood.
So far, most of network analysis approaches are based on
single-layer “Omics” data. However, our molecular and cellular
networks are in fact composed of various types of bulk of
molecules, such as genomic DNA, mitochondrial DNA, coding
mRNA, noncoding mRNA, proteins, metabolites and epigenetic
modiﬁcations. Furthermore, our bodies consist of not only our
own cells, also billions of symbiotic microorganisms that could be
beneﬁcial or pathologic to our immune systems (see above).
Therefore, it is urgent for us to integrate various types/layers of
“Omics” and clinical data119,120 to build more comprehensive
multi-scale and multi-layer network models to stratify patient
subgroups for the complex diseases of interest (Fig. 1, Step 3). To
reach that aim is still a long way to go due to the various reasons
such as high ﬁnancial cost, lack of appropriate computational
approaches, lack of common understanding of joint expertise, and
others.
Big-data management
To be more efﬁcient, compatible and secure, all medical and large-
scale “Omics” data sets of patients, whatever the diseases they are
concerning, will have to be digitized, integrated, structured,
centralized, secured, and standardized121 (in acronym, “DISCSS”,
Table 2). Not only is standardization in experimental and clinical
sampling procedures required, but also standardization in big data
formatting, description, repository, analysis, integration, and
sharing is vital to the success of personalized immunology (Table
2). Furthermore, high-resolution medical imaging data, behavior
and symptom/phenotypic data derived from social media122 and
wearable instruments and smart phones123 will generate unpre-
cedented ever-increasing volume of clinically related data. For this
purpose, dedicated integrated large-scale biomedical data man-
agement platforms,124 such as TranSMART,125,126 FAIRDOM127 and
others are badly needed for diverse clinical or preclinical studies.
International or national shared infrastructure on big-data storage,
analysis and training with the highest standards to maximize the
value of biomedical metadata, such as European collaboration to
handle data in life science, also well-known as ELIXIR128 and BD2K
(Big Data to Knowledge) initiative16 need to be further developed
and popularized across the world. This meets the e-health
concept, at least, by the European Commission within the frame
of the H2020 initiative (https://ec.europa.eu/digital-single-market/
en/policies/ehealth), shifting from physician-centered to patient-
centered healthcare. Compliance with legal and regulatory
aspects (General Data Protection Regulation for example) might
prevent or impair this cross-border e-health concept, which is
extremely important for Europe where mobility of workers across
different countries is becoming routine. Centralized patient ﬁles
with the explosive growth of molecular “Omics” data volumes will
require long-lasting update to technological capacities, such as
data storage space on servers, better and faster compression/
decompression algorithms and user-friendly accessibility for
physicians. General practitioners might not be able to afford
costs, which means that patients’ ﬁles would be accessible from
larger healthcare centers only. Hopefully, the health infrastructure
tomorrow should be transformed by, and eventually support the
implementation of personalized medicine.129
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Other miscellaneous challenges in implementation of
personalized immunology
Besides purely scientiﬁc and clinical aspects, implementation of
personalized immunology will imply the compliance of legal,
regulatory, social, and technical issues that will also be brieﬂy
addressed here.
Ethic and regulatory issues. Through “Omics” technologies
coupled to other systems biology approaches, huge amounts of
personal health data sets will be generated and shared. According
to current legislations on data privacy, a fully informed consent
(IC) of the patients is required for data processing within the frame
of duration-deﬁned speciﬁc purposes. The advent of personalized
medicine challenges this concept of IC, since it clearly implies
secondary data processing or re-processing according to the FAIR
principles (Findable, Accessible, Interoperable, and Reusable) of
the large-scale data management,106 which is now required or at
least recommended by NIH or EU funding agencies for the
submission of new proposals related to generation or analysis of
big biomedical data. Similarly, the discovery of predictive markers
might allow the researchers/clinicians to be aware of unavoidable
future diseases or debilitations. However, it remains unclear
whether according to the classic ICs given to analyze data in the
context of a particular disease, the patient should be informed of
newly discovered risks of suffering from other diseases that have
not been initially screened. Possibly, one should go for broad or
dynamic ICs, which is however either too labor-tedious or still not
well-accepted yet.130 Since the usage of freely-available social
media-derived clinical information is ever increasing, privacy
protection and anonymization of patients’ identiﬁcation131,132
might become impossible in the near future133 (Table 2). How will
the two aspects, i.e., patient data privacy, data sharing and ever-
expanding possible secondary-usage purposes be reconciled?
Clinical trials to assess the efﬁcacy and safety of candidate drugs
are currently still mainly based on the group-wised comparisons,
i.e., between the drug treated and placebo given groups (Table 2).
This will still need to be addressed when individual patients will be
treated with personalized drugs or vaccines or a combination of
therapies. New guidelines on how to evaluate drug efﬁcacies and
safeties will need to be developed in the era of personalized
medicine.
Cost issues. Identiﬁcation of biomarkers requires the in-depth
“Omics” characterization and stratiﬁcation of population cohorts
with sufﬁcient power of statistics. These potential biomarkers will
then need to be validated and correlated in different patient
subpopulations, according to multiple parameters such as sex,
age, ethnicity, and others.134 The implementation of personalized
immunology should result in a reduced social and ﬁnancial
burden through ﬁne-tuned patient stratiﬁcation into some
subgroups requiring simple and relatively cheap treatment, while
others demanding much more complicated and expensive
therapeutic alternatives (Table 2). Given the huge funding
required to achieve this goal, clear criteria will have to be set to
decide which diseases are worthy of these efforts. Most likely, the
decision will be made based on the prevalence of a disease
worldwide, or on the potential return of ﬁnancial investment.
However, since personalized immunology emphasizes personal
molecular characteristics, rare diseases might pop up eventually as
one of the focuses, which will further complicate these intuitive
considerations in cost. Since longitudinal cohort studies are vital
for simultaneously discovering various types of personal biomar-
kers, the current funding framework in many countries, which
often only lasts 3–5 years, should be adjusted as well. Last but not
least, it will be also challenging to adapt the current one-cut
pharmaceutical production pipelines to the ones meeting the
production requirements of personalized treatments (Table 2),
such as personal vaccines, which might alter the entire concept of
current manufacturing ﬂows and apparently, at least the short-
term return of investment.
CONCLUDING REMARKS
As outlined above, we discuss the multiple challenges and
propose a roadmap, not only in scientiﬁc and clinical aspects,
but also in big-data management, legal and regulatory sides
towards personalized immunology. Among others, multilayer
“Omics” analysis along longitudinal cohort studies are desperately
required to simultaneously obtain various types of reliable
biomarkers. Currently, approaches developed for patients’ sub-
group stratiﬁcation seem to be quite advanced relative to
personalized therapies. One of the essential barriers that should
be overcome in the near future is to translate patients’ subgroup
stratiﬁcation to personalized treatment. Currently, our success still
mainly binds with patient stratiﬁcation. Further developing both
clinically applicable measurement and computational analysis
approaches in personalized medicine is an incredible opportunity
to increase global health, provided that investment returns are
assessed not only in terms of ﬁnancial proﬁt, but also in terms of
patient well-being. In other words, we should give ourselves a
toolset to allow personalized immunology to be an advance for
the sake of health and wealth.
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